An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

Required: ATM mutation

ATM mutation

Required: ATM wild-type

ATM wild-type, with or without other DDR functional defects

Required: EGFR wild-type

Exclude subjects with known EGFR mutations

Required: ALK wild-type

Exclude subjects with known ALK mutations

Required: ROS1 wild-type

Exclude subjects with known ROS1 mutations

Required: BRAF wild-type

Exclude subjects with known BRAF mutations

Required: MET wild-type

Exclude subjects with known MET mutations

Required: RET wild-type

Exclude subjects with known RET mutations

Required: KRAS wild-type

Exclude subjects with known KRAS mutations

Required: NRAS wild-type

Exclude subjects with known NRAS mutations

Required: MSI MSS

Exclude KRAS/NRAS/BRAF mutations or MSI-H status

Must have received: anti-PD-(L)1 therapy — locally advanced or metastatic NSCLC

prior therapy with an anti-PD-(L)1-containing regimen (either as monotherapy or in combination)

Must have received: platinum-based chemotherapy — locally advanced or metastatic NSCLC

platinum-based doublet regimen for locally advanced or metastatic NSCLC

Must have received: platinum-based chemotherapy — recurrent or metastatic advanced endometrial cancer

at least one prior platinum-based chemotherapy

Must have received: immune checkpoint inhibitor (PD-1 or PD-L1) therapy — recurrent or metastatic advanced endometrial cancer

immune checkpoint inhibitor (PD-1 or PD-L1) therapy

Must have received: platinum-based chemotherapy combined with PD-(L)1 therapy — SCLC

progressed after platinum-based chemotherapy combined with PD-(L)1 therapy

Cannot have received: ATR inhibitors, ATM inhibitors, WEE1 inhibitors, CHK1/CHK2 inhibitors (TCC1727)

Prior treatment with TCC1727, other ATR inhibitors, or cell cycle checkpoint inhibitors (e.g., ATM inhibitors, WEE1 inhibitors, CHK1/CHK2 inhibitors)

Cannot have received: Olaparib (Olaparib Tablets)

Exception: Cohort 4 Subgroup 2 allows subjects who have not received Olaparib Tablets

Subjects who have experienced disease progression after prior Olaparib Tablets therapy (maintenance or subsequent therapy). Subjects must not have received further treatment after progression on Olaparib Tablets.